EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Risk of major birth defects after first‐trimester exposure to carbocisteine and ambroxol: A multicenter prospective cohort study using counseling data for drug safety during pregnancy

Mariko Usuda iD, Seung Chik Jwa, Mikako Goto iD, Mizuki Kobayashi, Hiroyuki Nagano, Naho Yakuwa iD, Ritsuko Yamane, Atsuko Murashima, Hideki Makabe

Congenital Anomalies · 2024

DOI: 10.1111/cga.12557 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Congenital Anomalies, 2024. Verfasst von Mariko Usuda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Pregnancy Trimester, First, Ambroxol, Abnormalities, Drug-Induced. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japanese Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To assess the risk of major birth defects after first‐trimester exposure to carbocisteine and ambroxol during pregnancy, we conducted a prospective cohort study using counseling data for drug use during pregnancy provided by the Japan Drug Information Institute in Pregnancy and Toranomon Hospital. Counseling information, including drug usage and participants' demographic information, was collected between April 1988 and December 2017. Pregnancy outcome data, including major birth defects, were obtained using a questionnaire administered 1 month after delivery. The risks of major birth defects after first‐trimester exposure to carbocisteine ( n = 588) and ambroxol ( n = 341) were compared with those of nonteratogenic drug use during the first trimester ( n = 1525). The adjusted odds ratio (aORs) for major birth defects was calculated using a multiple logistic regression analysis adjusted for confounders. The incidence of major birth defects was 1.2% (7/588) and 2.1% (7/341) in the carbocisteine and ambroxol groups, respectively, which was comparable to the control group (26/1525, 1.7%). Results of multiple logistic regression demonstrated similar nonsignificant risks for both carbocisteine (aOR: 0.66, 95% confidence interval [CI]: 0.40–1.1, p = 0.11) and ambroxol (aOR: 1.1, 95% CI: 0.18–7.2, p = 0.88). No specific major birth defects were reported in the carbocisteine or ambroxol groups. This study demonstrated that carbocisteine and ambroxol exposure during the first trimester was not associated with an increased risk of major birth defects. These results could help in counseling for the use of these drugs during pregnancy and further alleviate anxiety in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnancy Trimester, FirstAmbroxolAbnormalities, Drug-InducedHumansPregnancyFemaleProspective StudiesAdultJapanCounselingPregnancy OutcomeRisk FactorsIncidence

Stichwörter der Autor:innen

carbocisteinefirst trimesterobservational cohort studypregnancy outcomesteratogenicity

Substanzen

Ambroxol

Autor:innen und Institutionen

  • Department of Pharmacy, Saitama Medical University, Saitama, Japan.
  • Department of Obstetrics and Gynecology, Saitama Medical University, Saitama, Japan.
  • Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan.
  • The Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pharmacy, Toranomon Hospital, Tokyo, Japan.
  • Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.

ORCID-Profile: Mariko Usuda, Mikako Goto, Naho Yakuwa

Förderung

  • Japanese Agency for Medical Research and Development

Zitieren

APA

Usuda, M., Jwa, S. C., Goto, M., Kobayashi, M., Nagano, H., Yakuwa, N., Yamane, R., Murashima, A., & Makabe, H. (2024). Risk of major birth defects after first‐trimester exposure to carbocisteine and ambroxol: A multicenter prospective cohort study using counseling data for drug safety during pregnancy. Congenital Anomalies. https://doi.org/10.1111/cga.12557

Vancouver

Usuda M, Jwa SC, Goto M, Kobayashi M, Nagano H, Yakuwa N, et al. Risk of major birth defects after first‐trimester exposure to carbocisteine and ambroxol: A multicenter prospective cohort study using counseling data for drug safety during pregnancy. Congenital Anomalies. 2024. doi:10.1111/cga.12557

BibTeX
@article{Usuda2024,
  author = {Usuda, Mariko and Jwa, Seung Chik and Goto, Mikako and Kobayashi, Mizuki and Nagano, Hiroyuki and Yakuwa, Naho and Yamane, Ritsuko and Murashima, Atsuko and Makabe, Hideki},
  title = {Risk of major birth defects after first‐trimester exposure to carbocisteine and ambroxol: A multicenter prospective cohort study using counseling data for drug safety during pregnancy},
  journal = {Congenital Anomalies},
  year = {2024},
  doi = {10.1111/cga.12557}
}
Kostenlos starten →